You might also like
Boston Scientific Corporation is a global company that develops, manufactures, and markets medical devices for various interventional medical specialties . The company operates through two main segments: MedSurg and Cardiovascular, offering a diverse range of products . Boston Scientific's product portfolio includes devices for gastrointestinal, pulmonary, urological, neurological, and cardiovascular conditions, driven by strategic growth and expansion into emerging markets .
- Cardiology - Develops and markets medical devices for heart-related conditions, contributing significantly to the company's overall sales.
- Peripheral Interventions - Provides devices for treating peripheral vascular diseases, enhancing the company's cardiovascular offerings.
- Endoscopy - Focuses on devices for gastrointestinal and pulmonary conditions, supporting minimally invasive procedures.
- Urology - Offers medical devices for urological conditions, addressing a wide range of patient needs.
- Neuromodulation - Addresses neurological movement disorders and chronic pain through innovative device solutions.
-
Can you provide more details on the unanticipated observations that led to the temporary pause of the AVANT GUARD trial for FARAPULSE in drug-naïve persistent AF patients, and how might this impact your timeline for resuming enrollment and obtaining label expansion?
-
With new pulse field ablation (PFA) catheters entering the market, what specific strategies are you implementing to ensure that existing FARAPULSE customers remain loyal and to attract new users, especially given the competitive landscape?
-
In the U.S., your core Cardiac Rhythm Management (CRM) growth was below market. What factors contributed to this underperformance, and what actions are you taking to improve your position in this segment?
-
Regarding the upcoming presentation of the ACURATE neo2 trial data at TCT, if the results are not as positive as anticipated, how will this affect your TAVR strategy in the U.S., and what contingency plans do you have in place?
-
Given your expectation that pulse field ablation adoption may exceed the previously communicated range of 40% to 60% of global AF ablations by 2026, do you foresee any potential supply constraints, and how are you ensuring your manufacturing capacity can meet this increased demand?
Competitors mentioned in the company's latest 10K filing.
- Abbott Laboratories - Primary competitor in the medical device markets .
- Medtronic plc - Primary competitor in the medical device markets .
- Domestic medical device companies in certain countries, particularly in China, which may benefit from their status as local suppliers .
- Non-medical device companies offering alternative therapies or technologies that could augment or replace procedures using Boston Scientific's products .
- Pharmaceutical companies, biotech companies, and providers of various diagnostic tests offering alternative therapies or diagnostics .